Concepedia

Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models

Ute Hoch, Carl‐Michael Staschen, Randall K. Johnson, Michael A. Eldon

Cancer Chemotherapy and Pharmacology · 2014 · 54 citations · 31 references

DOIFull text

Open access

Abstract

Etirinotecan pegol is the first long-acting topoisomerase 1 inhibitor that provides sustained exposure, which results in prolonged anti-tumor activity in a wide variety of cancer models.

References

31

Dose translation from animal to human studies revisited

Shannon Reagan‐Shaw, Minakshi Nihal, Nihal Ahmad · The FASEB Journal · 2007 · 6.1K citations

, , +19

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

J-Y Douillard, David Cunningham, AD Roth et al. · The Lancet · 2000 · 3.3K citations

, , +6

Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

Leonard B. Saltz, John V. Cox, Charles D. Blanke et al. · New England Journal of Medicine · 2000 · 3K citations · Full text

Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.

Yasuyoshi Kawato, Masashi Aonuma, Yasuhide Hirota et al. · PubMed · 1991 · 874 citations

, , +12

Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

Nasser H. Hanna, Paul A. Bunn, Corey J. Langer et al. · Journal of Clinical Oncology · 2006 · 673 citations · Full text